ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
US Tech 100
17,446.00
2.17%
Dow Jones
38,675.68
1.18%
Brent Oil
82.765
0.00%
Bitcoin
63,359.58
-0.83%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE

  6. Neurones Sa (0GX2) Quote

Neurones Sa

Neurones Sa (0GX2)

LSE
25.90
0.00
(0.00%)
Closed May 05 11:30AM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
25.90
Bid
0.00
Ask
0.00
Volume
46
0.00 Day's Range 0.00
25.90 52 Week Range 25.90
Market Cap
1.106B
Previous Close
25.90
Open
-
Last Trade
11
@
45.65
(O)
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
479
Shares Outstanding
24,228,000
Dividend Yield
-
PE Ratio
25.00
Earnings Per Share (EPS)
1.83
Revenue
668.38M
Net Profit
44.24M

About Neurones Sa

Sector
Computer Programming Service
Industry
Computer Programming Service
Website
www.neurones.net
Headquarters
Nanterre, Hauts-de-seine, Fra
Founded
1970
Neurones Sa is listed in the Computer Programming Service sector of the London Stock Exchange with ticker 0GX2. The last closing price for Neurones was 25.90 €. Over the last year, Neurones shares have traded in a share price range of 25.90 € to 25.90 €.

Neurones currently has 24,228,000 shares outstanding. The market capitalization of Neurones is 1.11 € billion. Neurones has a price to earnings ratio (PE ratio) of 25.00.

0GX2 Latest News

More News

NEURONES : Mise à disposition du Document d’Enregistrement Universel 2023

NEURONES : Mise à disposition du Document d’Enregistrement Universel 2023 INFORMATION PRESSE Rubrique : Document d’Enregistrement Universel 2023 Nanterre, le 25 avril 2024 Mise à...

April 25 2024
GlobeNewswire Inc.

NEURONES : Résultat net part du groupe en croissance de + 11,5% en 2023

NEURONES : Résultat net part du groupe en croissance de + 11,5% en 2023 INFORMATION PRESSERubrique : Résultats annuels 2023        Nanterre, le 6 mars 2024 (après Bourse) Résultat net part du...

March 06 2024
UK Regulatory

NEURONES: Net profit (group share) up 11.5% in 2023

NEURONES: Net profit (group share) up 11.5% in 2023 PRESS INFORMATIONHeading: 2023 annual results        Nanterre, March 6, 2024 (after trading) Net profit (group share) up 11.5% in 2023...

March 06 2024
UK Regulatory

NEURONES: 11.1% organic growth in 2023

NEURONES: 11.1% organic growth in 2023 PRESS INFORMATIONHeading: 2023 annual revenues        Nanterre, February 7, 2024 (after trading) 11.1% organic growth in 2023 (being audited, in €...

February 07 2024
UK Regulatory

NEURONES : + 11,1% de croissance organique en 2023

NEURONES : + 11,1% de croissance organique en 2023 INFORMATION PRESSERubrique : C.A. annuel 2023        Nanterre, le 7 février 2024 (après Bourse) + 11,1% de croissance organique en 2023 (en...

February 07 2024
UK Regulatory

NEURONES : Programme de rachat d'actions - Lancement effectif

NEURONES : Programme de rachat d'actions - Lancement effectif INFORMATION PRESSERubrique : Rachat d’actions        Nanterre, le 12 décembre 2023 (après Bourse) PROGRAMME DE RACHAT...

December 12 2023
GlobeNewswire Inc.

NEURONES : + 12,3% de croissance organique en cumul à la fin du 3e trimestre 2023

NEURONES : + 12,3% de croissance organique en cumul à la fin du 3e trimestre 2023 INFORMATION PRESSERubrique : C.A. 3e trimestre 2023        Nanterre, le 8 novembre 2023 (après Bourse...

November 08 2023
GlobeNewswire Inc.

NEURONES - Rapport financier premier semestre 2023

NEURONES - Rapport financier premier semestre 2023 NEURONES - Rapport financier premier semestre 2023 Pièce jointe NEURONES-rapport-financier-premier-semestre-2023

September 07 2023
GlobeNewswire Inc.

NEURONES : 8,1% de résultat net au 1er semestre 2023

NEURONES : 8,1% de résultat net au 1er semestre 2023 INFORMATION PRESSERubrique : Résultats 1er semestre 2023        Nanterre, le 6 septembre 2023 (après Bourse) 8,1% de résultat net au 1er...

September 06 2023
GlobeNewswire Inc.

NEURONES : + 12,9% de croissance organique au 1er semestre 2023

NEURONES : + 12,9% de croissance organique au 1er semestre 2023 INFORMATION PRESSE        Nanterre, le 2 août 2023 (après Bourse)Rubrique : C.A. 1er semestre 2023 + 12,9% de croissance...

August 02 2023
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10025.925.925.920225.9DE
40025.925.925.924525.9DE
120025.925.925.947925.9DE
260025.925.925.969325.9DE
520025.925.925.943125.9DE
1560025.925.925.931325.9DE
2600025.925.925.962725.9DE

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BENFBeneficient
$ 6.8001
(254.17%)
31.01M
SGBXSafe and Green Holdings Corporation
$ 5.49
(87.37%)
92.18M
SHOTWSafety Shot Inc
$ 0.45
(45.16%)
644
AIPArteris Inc
$ 8.185
(38.03%)
1.11M
RGFReal Good Food Company Inc
$ 0.85
(37.32%)
4.26M
MNDRMobile health Network Solutions
$ 3.33
(-84.91%)
18.76M
NUVOHoldco Nuvo Group DG Ltd
$ 2.00
(-57.54%)
1.04M
SPTSprout Social Inc
$ 28.82
(-40.15%)
13.47M
UNITUniti Group Inc
$ 4.441
(-26.35%)
21.07M
IPDNProfessional Diversity Network Inc
$ 1.29
(-24.12%)
662.59k
AAPLApple Inc
$ 183.38
(5.98%)
163.22M
SQQQProShares UltraPro Short QQQ
$ 11.08
(-5.94%)
154.59M
JAGXJaguar Health Inc
$ 0.3164
(7.91%)
142.47M
NKLANikola Corporation
$ 0.6526
(6.55%)
106.88M
SGBXSafe and Green Holdings Corporation
$ 5.49
(87.37%)
92.18M

Discussion

View Full Feed
shoondale shoondale 7 minutes ago
So you say. Allow others to interpret the article and its relevance, or lack thereof to the OTC and MGON as they please.
MGON
rbtree rbtree 8 minutes ago
Good luck with that....total fantasy.
KEGS
Acme Investments Acme Investments 10 minutes ago
Hindsight is 20/20!! I definitely would have done the same thing!! Here's my conspiracy theory.......we will get another run around election time!! Although I don't think it will be as big!! That was pandemic pay but I had no idea it was supposed to last for almost 4 years!! Lol 😂
CRCW
dragoon76 dragoon76 13 minutes ago
OK, share your DD on why he's FOS. I'm curious to learn what you know/have. Maybe it is something I've never considered.
COOP
4u2nv2 4u2nv2 14 minutes ago
And I am looking forward to the answer. It's time........................
MCIC
blackhawks blackhawks 17 minutes ago
That's another thing, the right ALWAYS believes something is being suppressed, something is being hidden.

The clinical data is out there. The FDA routinely pulls lethal pharmaceuticals from the markets. They REQUIRE that the TV ads mention the worst side effects no matter how few inc
DJT
Acme Investments Acme Investments 17 minutes ago
Either you think it's coming back or not!! The time frame doesn't matter!! Everyone who invested knew the risks involved and that included the possibility of it taking years to develop!!
WNFT
lager lager 20 minutes ago
My grandma made great Mac and cheese. Carvana had great Q1 results. MGON not related to those two things. But thought I would post anyway.
MGON
theorysuit theorysuit 20 minutes ago
Doing loans with streetville, cashing in on warrants etc....where is all the money going. Mgmt needs to answer or else....

Or else what. You aren't going to get any answers with this company. Secrecy and subterfuge is their MO. Their purpose is to give themselves millions of do
NWBO
shoondale shoondale 21 minutes ago
Excellent question. I wonder if that would answer my previous question about why taking over a tainted shell? It probably is legal although I am not sure. I did not think to ask if he already a percentage of the company.
NWGC
lager lager 22 minutes ago
Didn't see MGON in that post. Elaborate please.
MGON
Gusher405 Gusher405 24 minutes ago
LOL

Let’s Go DBMM!
DBMM
ace65 ace65 29 minutes ago
Dead cat incoming ...lol.
TWOH
janice shell janice shell 29 minutes ago
It's all part of the experience. You didn't get to Central Park, did you?
littlejohn littlejohn 31 minutes ago
Oxy needs to find a sucker like VTLE

to over pay what a property

may actually be worth now...

https://finance.yahoo.com/news/occidental-explores-sale-permian-assets-152814126.html

High interest rates, low natural gas

prices,
janice shell janice shell 31 minutes ago
(3) the jury did not could not find the evidence to convict him of rape

There was no jury. It was a bench trial. That was because his lawyers forgot to request a jury trial. Probably that idiot Habba

And you obviously don't understand any of the rest of it, either.
johnydollar johnydollar 32 minutes ago
Leon Coffee is a more entertaining 🤡 than this guys.......

He has been hit many a times........

And he is still laughing........

https://youtu.be/ZPpxY3Wl1-o?si=0nQibOm87KRvC-PL
DBMM
shoondale shoondale 32 minutes ago
👍️SEC👍️ Charges Rhode Island Stock Promoter with Microcap Fraud
https://www.sec.gov/litigation/litreleases/lr-25993 https://www.sec.gov/litigation/litreleases/lr-25993
The companies in question are SOLY, CNSP, EBET, VLCN, TOBAF
The Securities and Exchange Comm
CNSP EBET VLCN
Jaxxm Jaxxm 32 minutes ago
EARI(.0003)~Asset $35 Million, $Rev. 3.5 million, 1.3B O/S~DD

1) The EARI Beverage Group is a diversified beverage group with 9 sub companies.

https://earigroup.com/about
https://www.otcmarkets.com/stock/EARI/profile

2) The company recently acquire
EARI REV
Acme Investments Acme Investments 32 minutes ago
You didn't answer the question!! Too busy trying to lecture foolishness!! I'm not in Canada so I can't buy in the expert market!!
WNFT

Your Recent History

LSE
0GX2
Neurones
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved